This HTML5 document contains 163 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n15http://linked.opendata.cz/resource/mesh/concept/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/pharmgkb/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/wikipedia/
foafhttp://xmlns.com/foaf/0.1/
n9http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n31http://linked.opendata.cz/resource/drugbank/mixture/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/bindingdb/
n4http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/kegg-compound/
n32http://www.drugs.com/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/pubchem-compound/
n20http://bio2rdf.org/drugbank:
n12http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/pubchem-substance/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n29http://www.rxlist.com/cgi/generic/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/iuphar/
n34http://linked.opendata.cz/resource/drugbank/patent/
n33http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/guide-to-pharmacology/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/medicinal-product/
n5http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/national-drug-code-directory/
n14http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n7http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/chemspider/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00341/identifier/chebi/
n30http://linked.opendata.cz/resource/atc/
n21http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00341
rdf:type
n7:Drug
n7:description
A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects. [PubChem]
n7:dosage
n26:271B5AB8-363D-11E5-9242-09173F13E4C5 n26:271B5AB9-363D-11E5-9242-09173F13E4C5 n26:271B5ABA-363D-11E5-9242-09173F13E4C5 n26:271B5ABB-363D-11E5-9242-09173F13E4C5 n26:271B5AB5-363D-11E5-9242-09173F13E4C5 n26:271B5AB6-363D-11E5-9242-09173F13E4C5 n26:271B5AB7-363D-11E5-9242-09173F13E4C5
n7:group
approved
n7:halfLife
8.3 hours
n7:indication
For the relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis and the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria
n7:manufacturer
n9:271B5A91-363D-11E5-9242-09173F13E4C5 n9:271B5A92-363D-11E5-9242-09173F13E4C5 n9:271B5A8F-363D-11E5-9242-09173F13E4C5 n9:271B5A90-363D-11E5-9242-09173F13E4C5 n9:271B5A95-363D-11E5-9242-09173F13E4C5 n9:271B5A96-363D-11E5-9242-09173F13E4C5 n9:271B5A93-363D-11E5-9242-09173F13E4C5 n9:271B5A94-363D-11E5-9242-09173F13E4C5 n9:271B5A8E-363D-11E5-9242-09173F13E4C5 n9:271B5AA9-363D-11E5-9242-09173F13E4C5 n9:271B5AA7-363D-11E5-9242-09173F13E4C5 n9:271B5AA8-363D-11E5-9242-09173F13E4C5 n9:271B5AA1-363D-11E5-9242-09173F13E4C5 n9:271B5AA2-363D-11E5-9242-09173F13E4C5 n9:271B5A9F-363D-11E5-9242-09173F13E4C5 n9:271B5AA0-363D-11E5-9242-09173F13E4C5 n9:271B5AA5-363D-11E5-9242-09173F13E4C5 n9:271B5AA6-363D-11E5-9242-09173F13E4C5 n9:271B5AA3-363D-11E5-9242-09173F13E4C5 n9:271B5AA4-363D-11E5-9242-09173F13E4C5 n9:271B5A99-363D-11E5-9242-09173F13E4C5 n9:271B5A9A-363D-11E5-9242-09173F13E4C5 n9:271B5A97-363D-11E5-9242-09173F13E4C5 n9:271B5A98-363D-11E5-9242-09173F13E4C5 n9:271B5A9D-363D-11E5-9242-09173F13E4C5 n9:271B5A9E-363D-11E5-9242-09173F13E4C5 n9:271B5A9B-363D-11E5-9242-09173F13E4C5 n9:271B5A9C-363D-11E5-9242-09173F13E4C5
owl:sameAs
n20:DB00341 n33:DB00341
dcterms:title
Cetirizine
adms:identifier
n4:C07778 n5:16714-271-02 n6:1222 n10:1222 n11:2678 n12:46508368 n13:22890 n16:DB00341 n17:3561 n18:2577 n24:PA448905 n25:Cetirizine
n7:mechanismOfAction
Cetirizine competes with histamine for binding at H<sub>1</sub>-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The low incidence of sedation can be attributed to reduced penetration of cetirizine into the CNS as a result of the less lipophilic carboxyl group on the ethylamine side chain.
n7:packager
n9:271B5A7D-363D-11E5-9242-09173F13E4C5 n9:271B5A7E-363D-11E5-9242-09173F13E4C5 n9:271B5A7B-363D-11E5-9242-09173F13E4C5 n9:271B5A7C-363D-11E5-9242-09173F13E4C5 n9:271B5A79-363D-11E5-9242-09173F13E4C5 n9:271B5A7A-363D-11E5-9242-09173F13E4C5 n9:271B5A77-363D-11E5-9242-09173F13E4C5 n9:271B5A78-363D-11E5-9242-09173F13E4C5 n9:271B5A85-363D-11E5-9242-09173F13E4C5 n9:271B5A86-363D-11E5-9242-09173F13E4C5 n9:271B5A83-363D-11E5-9242-09173F13E4C5 n9:271B5A84-363D-11E5-9242-09173F13E4C5 n9:271B5A81-363D-11E5-9242-09173F13E4C5 n9:271B5A82-363D-11E5-9242-09173F13E4C5 n9:271B5A7F-363D-11E5-9242-09173F13E4C5 n9:271B5A80-363D-11E5-9242-09173F13E4C5 n9:271B5A8D-363D-11E5-9242-09173F13E4C5 n9:271B5A8B-363D-11E5-9242-09173F13E4C5 n9:271B5A8C-363D-11E5-9242-09173F13E4C5 n9:271B5A89-363D-11E5-9242-09173F13E4C5 n9:271B5A8A-363D-11E5-9242-09173F13E4C5 n9:271B5A87-363D-11E5-9242-09173F13E4C5 n9:271B5A88-363D-11E5-9242-09173F13E4C5 n9:271B5A65-363D-11E5-9242-09173F13E4C5 n9:271B5A66-363D-11E5-9242-09173F13E4C5 n9:271B5A63-363D-11E5-9242-09173F13E4C5 n9:271B5A64-363D-11E5-9242-09173F13E4C5 n9:271B5A61-363D-11E5-9242-09173F13E4C5 n9:271B5A62-363D-11E5-9242-09173F13E4C5 n9:271B5A5F-363D-11E5-9242-09173F13E4C5 n9:271B5A60-363D-11E5-9242-09173F13E4C5 n9:271B5A6D-363D-11E5-9242-09173F13E4C5 n9:271B5A6E-363D-11E5-9242-09173F13E4C5 n9:271B5A6B-363D-11E5-9242-09173F13E4C5 n9:271B5A6C-363D-11E5-9242-09173F13E4C5 n9:271B5A69-363D-11E5-9242-09173F13E4C5 n9:271B5A6A-363D-11E5-9242-09173F13E4C5 n9:271B5A67-363D-11E5-9242-09173F13E4C5 n9:271B5A68-363D-11E5-9242-09173F13E4C5 n9:271B5A75-363D-11E5-9242-09173F13E4C5 n9:271B5A76-363D-11E5-9242-09173F13E4C5 n9:271B5A73-363D-11E5-9242-09173F13E4C5 n9:271B5A74-363D-11E5-9242-09173F13E4C5 n9:271B5A71-363D-11E5-9242-09173F13E4C5 n9:271B5A72-363D-11E5-9242-09173F13E4C5 n9:271B5A6F-363D-11E5-9242-09173F13E4C5 n9:271B5A70-363D-11E5-9242-09173F13E4C5
n7:patent
n34:6455533
n7:synonym
Cetirizin Cetirizina Cetirizinum
n7:toxicity
Somnolence (sleepiness or unusual drowsiness), restlessness, irritability
n21:hasAHFSCode
n22:04-08-00
n7:foodInteraction
Avoid alcohol. Take without regard to meals.
n7:mixture
n31:271B5A5E-363D-11E5-9242-09173F13E4C5
n7:proteinBinding
Very high (93%) plasma protein binding
n7:synthesisReference
Manne Reddy, "Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof." U.S. Patent US20040186112, issued September 23, 2004.
n14:hasConcept
n15:M0026321
foaf:page
n29:cetiriz.htm n32:cetirizine-hcl.html
n7:IUPAC-Name
n8:271B5AC0-363D-11E5-9242-09173F13E4C5
n7:InChI
n8:271B5AC6-363D-11E5-9242-09173F13E4C5
n7:Molecular-Formula
n8:271B5AC5-363D-11E5-9242-09173F13E4C5
n7:Molecular-Weight
n8:271B5AC2-363D-11E5-9242-09173F13E4C5
n7:Monoisotopic-Weight
n8:271B5AC3-363D-11E5-9242-09173F13E4C5
n7:SMILES
n8:271B5AC4-363D-11E5-9242-09173F13E4C5
n7:Water-Solubility
n8:271B5ABE-363D-11E5-9242-09173F13E4C5 n8:271B5AD6-363D-11E5-9242-09173F13E4C5
n7:logP
n8:271B5ABF-363D-11E5-9242-09173F13E4C5 n8:271B5ABC-363D-11E5-9242-09173F13E4C5 n8:271B5AD8-363D-11E5-9242-09173F13E4C5
n7:logS
n8:271B5ABD-363D-11E5-9242-09173F13E4C5
n21:hasATCCode
n30:R06AE07
n7:H-Bond-Acceptor-Count
n8:271B5ACC-363D-11E5-9242-09173F13E4C5
n7:H-Bond-Donor-Count
n8:271B5ACD-363D-11E5-9242-09173F13E4C5
n7:InChIKey
n8:271B5AC7-363D-11E5-9242-09173F13E4C5
n7:Polar-Surface-Area--PSA-
n8:271B5AC8-363D-11E5-9242-09173F13E4C5
n7:Polarizability
n8:271B5ACA-363D-11E5-9242-09173F13E4C5
n7:Refractivity
n8:271B5AC9-363D-11E5-9242-09173F13E4C5
n7:Rotatable-Bond-Count
n8:271B5ACB-363D-11E5-9242-09173F13E4C5
n7:absorption
mean peak plasma concentration (Cmax) of 114 ng/mL at a time (Tmax) of 2.2 hours postdose was observed for cetirizine
n7:affectedOrganism
Humans and other mammals
n7:casRegistryNumber
83881-51-0
n7:category
n7:clearance
* 53 mL/min [healthy]
n7:containedIn
n23:271B5AAC-363D-11E5-9242-09173F13E4C5 n23:271B5AAD-363D-11E5-9242-09173F13E4C5 n23:271B5AAA-363D-11E5-9242-09173F13E4C5 n23:271B5AAB-363D-11E5-9242-09173F13E4C5 n23:271B5AB4-363D-11E5-9242-09173F13E4C5 n23:271B5AB2-363D-11E5-9242-09173F13E4C5 n23:271B5AB3-363D-11E5-9242-09173F13E4C5 n23:271B5AB0-363D-11E5-9242-09173F13E4C5 n23:271B5AB1-363D-11E5-9242-09173F13E4C5 n23:271B5AAE-363D-11E5-9242-09173F13E4C5 n23:271B5AAF-363D-11E5-9242-09173F13E4C5
n7:Bioavailability
n8:271B5AD2-363D-11E5-9242-09173F13E4C5
n7:Ghose-Filter
n8:271B5AD4-363D-11E5-9242-09173F13E4C5
n7:MDDR-Like-Rule
n8:271B5AD5-363D-11E5-9242-09173F13E4C5
n7:Melting-Point
n8:271B5AD7-363D-11E5-9242-09173F13E4C5
n7:Number-of-Rings
n8:271B5AD1-363D-11E5-9242-09173F13E4C5
n7:Physiological-Charge
n8:271B5AD0-363D-11E5-9242-09173F13E4C5
n7:Rule-of-Five
n8:271B5AD3-363D-11E5-9242-09173F13E4C5
n7:Traditional-IUPAC-Name
n8:271B5AC1-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-acidic-
n8:271B5ACE-363D-11E5-9242-09173F13E4C5
n7:pKa--strongest-basic-
n8:271B5ACF-363D-11E5-9242-09173F13E4C5